TMFM - ETF AI Analysis
Top Page
Motley Fool Mid-Cap Growth ETF (TMFM)
Rating:69Neutral
Price Target:―
Positive Factors
Strong AUM Base
The fund has built a solid asset base, suggesting it has attracted a meaningful level of investor interest and support.
Leading Growth Holdings
Several top positions, including Datadog, StoneX Group, West Pharmaceutical Services, Dexcom, and Healthequity, have shown strong year-to-date performance, helping support the ETF’s returns.
Sector Diversification Across Growth Areas
The ETF spreads its investments across technology, health care, industrials, financials, and other sectors, which helps reduce the impact if any single industry faces a downturn.
Negative Factors
High Expense Ratio
The fund’s expense ratio is relatively high for an ETF, which means more of the returns are eaten up by fees over time.
Mixed Performance So Far This Year
Year-to-date performance has been weak, with only a small recent one-month rebound and flat three-month results, which may concern investors looking for steady growth.
Concentration in a Few Mid-Cap Growth Names
The top holdings make up a significant portion of the portfolio and include several lagging stocks like Guidewire, Axon Enterprise, Toast, and Brown & Brown, increasing the fund’s sensitivity to the fortunes of these individual companies.
TMFM vs. SPDR S&P 500 ETF (SPY)
AUM119.33M
RegionNorth America
Expense Ratio0.85%
Beta0.94
IssuerMotley Fool
Inception DateDec 10, 2021
Dividend Yield0.06%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume7,032
30 Day Avg. Volume10,109
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
28.24Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering34
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TMFM Summary
The Motley Fool Mid-Cap Growth ETF (TMFM) is an actively managed fund that focuses on medium‑sized U.S. companies with strong growth potential, rather than tracking a traditional index. It leans heavily toward technology and health care businesses, including well-known names like Dexcom and Datadog. Investors might consider TMFM if they want to diversify into mid-sized companies that could grow into the next generation of large, leading firms. However, because it concentrates on growth stocks and specific sectors, its share price can rise and fall more sharply than the overall market.
How much will it cost me?The Motley Fool Mid-Cap Growth ETF (TMFM) has an expense ratio of 0.85%, meaning you’ll pay $8.50 per year for every $1,000 invested. This is higher than average because it is actively managed, relying on expert stock-picking to target mid-cap growth companies with strong potential.
What would affect this ETF?The TMFM ETF, with its focus on U.S. mid-cap growth companies, could benefit from advancements in technology and innovation, particularly as its largest sector exposure is technology. Positive economic conditions and increased consumer spending may also support growth in sectors like industrials and financials. However, rising interest rates or regulatory changes could negatively impact growth-focused companies, especially in sectors like real estate and financials, which are sensitive to such factors.
TMFM Top 10 Holdings
TMFM leans heavily into U.S. mid-cap growth, with a clear tilt toward tech and health care names that are setting the tone for returns. Datadog has been a standout, powering higher on strong momentum, while StoneX has quietly added fuel with steady gains over time. HealthEquity and Dexcom are also rising, giving the fund a solid health-tech backbone. On the flip side, Guidewire and Toast have been lagging, acting like a bit of a brake on performance. Overall, it’s a concentrated bet on innovative, U.S.-based growth stories.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Dexcom | 5.55% | $6.63M | $31.98B | 12.59% | 79 Outperform | |
| Healthequity | 5.50% | $6.58M | $8.75B | 15.50% | 76 Outperform | |
| Guidewire | 4.85% | $5.79M | $14.20B | -17.22% | 63 Neutral | |
| West Pharmaceutical Services | 4.84% | $5.79M | $24.92B | 46.52% | 68 Neutral | |
| Toast Inc | 4.64% | $5.54M | $20.03B | -17.50% | 73 Outperform | |
| Axon Enterprise | 4.55% | $5.44M | $46.39B | -27.16% | 58 Neutral | |
| GXO Logistics | 4.13% | $4.94M | $5.53B | -6.36% | 68 Neutral | |
| MongoDB | 4.04% | $4.83M | $32.08B | 107.30% | 75 Outperform | |
| QXO Inc | 3.96% | $4.73M | $16.77B | -20.19% | 66 Neutral | |
| Brown & Brown | 3.95% | $4.72M | $23.90B | -24.31% | 76 Outperform |
TMFM Technical Analysis
Positive
―
Price Trends
21.81
Positive
21.30
Positive
22.17
Positive
Market Momentum
0.46
Negative
66.09
Neutral
93.93
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TMFM, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 22.30, equal to the 50-day MA of 21.81, and equal to the 200-day MA of 22.17, indicating a bullish trend. The MACD of 0.46 indicates Negative momentum. The RSI at 66.09 is Neutral, neither overbought nor oversold. The STOCH value of 93.93 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TMFM.
TMFM Peer Comparison
Comparison Results
Performance Comparison
TMFM
Motley Fool Mid-Cap Growth ETF
23.52
-2.13
-8.30%
AVMV
Avantis U.S. Mid Cap Value ETF
―
―
―
AVMC
Avantis U.S. Mid Cap Equity ETF
―
―
―
GLRY
Inspire Faithward Mid Cap Momentum ESG ETF
―
―
―
FRTY
Alger Mid Cap 40 ETF
―
―
―
MID.ETF
American Century Mid Cap Growth Impact ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents